You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

Displaying 101 - 110 of 201422 results
  1. Multivalent Adjuvant Immunization to Prevent Hospital Acquired Infections

    SBC: EXBAQ LLC            Topic: NIAID

    PROJECT SUMMARY/ABSTRACT Two million Healthcare Associated Infections (HAIs) occur per year in the US, killing andgt;90,000 patients and costing ~$50-100 billion (adjusted by CPI to 2020 dollars). HAIs are the 6th leading cause of death in the US, ahead of diabetes and kidney disease. Reducing HAIs is a top priority of the US Department of Health and Human Services1 and experts have called for nov ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  2. Optimizing a Stapled-Peptide That Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NIAID

    ABSTRACT Infection of the eye by Herpes Simplex Virus-1 (HSV-1) can result in Herpes Keratitis (HK), which is the leading cause of infectious corneal blindness worldwide. In the U.S., nearly 500,000 individuals experience ocular herpes infections that are often recurrent and culminate in progressive corneal scarring and loss of vision. The gold standard treatment is Acyclovir (ACV) that targets HS ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  3. Nonclinical Development of an Improved Polio Vaccine

    SBC: BIOLOGICAL MIMETICS INC            Topic: NIAID

    AbstractIn an SBIR Phase II, we developed an improved polio vaccine candidate, primarily for use in the post-eradication era. We call the candidate, ultraIPVTM, because it is produced using a UVC- inactivation method. UltraIPVTM has major improvements compared to existing IPV products, such as IPOL (Sanofi) and VeroPol (Staten Serum Institute). The ultraIPVTM technology is compatible with attenuat ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  4. Commercial Readiness of a CI NR algorithm

    SBC: York Sound Inc            Topic: NIDCD

    PROJECT SUMMARY / ABSTRACTCochlear implant (CI) users are typically able to maintain conversations in quiet environments. However, when multiple people are talking simultaneously, such as at a large family dinner or in a restaurant, CI users have great difficulty participating in conversations and frequently withdraw or avoid the situation. Ideally, CI algorithms to remove background talkers (“b ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  5. Multi-site longitudinal Integrated Neurocognitive and Sleep-Behavior Profiler for the Endophenotypic Classification of Dementia Subtypes (INSPECDS)

    SBC: ADVANCED BRAIN MONITORING, INC.            Topic: NIA

    It is estimated that Alzheimer’s and other neurodegenerative diseases causing dementia will surpass cancer as the second leading cause of death by the year 2040. Alzheimer’s disease (AD) is the leading cause of dementia, followed by synucleinopathies, including dementia with Lewy bodies (DLB), Parkinson’s disease with dementia (PDD), and Fronto-temporal dementia. There is an urgent, unmet ne ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  6. miRNA drug for tendinopathy

    SBC: NEW YORK R&D CENTER FOR TRANSLATIONAL MEDICINE AND THERAPEUTICS, INC.            Topic: R

    Project SummaryTendinopathy is a tendon disorder that is highly prevalent in the aged population. It is characterized by tendon deterioration that often leads to tendon rupture, and is associated with pain, swelling and impaired performance. There is currently no cure for tendinopathy and an urgent need for effective treatments for tendinopathy. The technology to be developed is microRNA (miR)-221 ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  7. A low cost and effective foot orthotics fabrication framework

    SBC: Xyken, LLC            Topic: NIA

    Project Summary:We propose in this SBIR effort to develop a direct 3D mobile imaging based foot orthotics optimization system for clinicians to treat and prevent chronic conditions such as diabetic ulceration and malalignment. The proposed system leaps beyond the traditional orthotics production process, as it allows clinicians to directly and conveniently acquire patients' 3D foot structure from ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  8. WayToServe Plus: In-service Professional Development Component to Improve Responsible Alcohol Service

    SBC: KLEIN BUENDEL, INC            Topic: 400

    Among the interventions targeting driving while intoxicated (DWI) by alcohol, Responsible Beverage Service (RBS) training of alcohol servers has shown promise. RBS training is currently required or incentivized by 36 U.S. states and California will require it starting in 2022. Our team has shown that an online RBS training, named WayToServe®, was effective in two randomized trials. These results ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  9. Process development for Cross Mode Coupling of Optical Fibers

    SBC: Q-PEAK INCORPORATED            Topic: N201044

    In this SBIR program, Q-Peak will develop a continuous manufacturing process to facilitate deterministic cross coupling between optical fibers.  The process will allow managing mode coupling in two-fiber sensor architectures, coupling of power from pump fibers to gain fibers for fiber lasers in a distributed length methodology and formation of unique signal add/drop functionality for optical netw ...

    SBIR Phase II 2022 Department of DefenseDefense Advanced Research Projects Agency
  10. Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics

    SBC: Chicago Biosolutions, Inc.            Topic: NIAID

    Influenza A viruses belong to the orthomyxoviridae family, and have a negative-sense, segmented RNA genome, which can cause seasonal or pandemic flu with high morbidity and significant mortality. Vaccination is the most prevalent prophylactic means for controlling influenza infections. However, an effective vaccine usually takes at least six months to develop. Furthermore, vaccination has limited ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government